Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
738.05
-3.40 (-0.46%)
Feb 2, 2026, 9:30 AM EST - Market open
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
$949,484
Profits / Employee
$298,219
Market Cap
75.72B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | 8,100 | 700 | 9.46% |
| Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
| Dec 31, 2017 | 6,200 | 800 | 14.81% |
| Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
| Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
| Dec 31, 2014 | 2,925 | 585 | 25.00% |
| Dec 31, 2013 | 2,340 | 390 | 20.00% |
| Dec 31, 2012 | 1,950 | 246 | 14.44% |
| Dec 31, 2011 | 1,704 | 309 | 22.15% |
| Dec 31, 2010 | 1,395 | 366 | 35.57% |
| Dec 31, 2009 | 1,029 | 110 | 11.97% |
| Dec 31, 2008 | 919 | 237 | 34.75% |
| Dec 31, 2007 | 682 | 109 | 19.02% |
| Dec 31, 2006 | 573 | -15 | -2.55% |
| Dec 31, 2005 | 588 | -142 | -19.45% |
| Dec 31, 2004 | 730 | 86 | 13.35% |
| Dec 31, 2003 | 644 | -25 | -3.74% |
| Dec 31, 2002 | 669 | 94 | 16.35% |
| Dec 31, 2001 | 575 | 84 | 17.11% |
| Dec 31, 2000 | 491 | 54 | 12.36% |
| Dec 31, 1999 | 437 | 66 | 17.79% |
| Dec 31, 1998 | 371 | 101 | 37.41% |
| Dec 31, 1997 | 270 | 27 | 11.11% |
| Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 11,000 |
| BioNTech SE | 6,772 |
| Vertex Pharmaceuticals | 6,100 |
| Moderna | 5,800 |
| Genmab | 2,681 |
| Incyte | 2,617 |
| Alnylam Pharmaceuticals | 2,230 |
| argenx SE | 1,599 |
REGN News
- 2 hours ago - EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases - GlobeNewsWire
- 2 days ago - Regeneron: Expect Double-Digit Growth In 2026 - Seeking Alpha
- 2 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Regeneron bets added cholesterol benefit will help its obesity drug stand out - Reuters
- 2 days ago - Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory - Benzinga
- 3 days ago - Regeneron beats quarterly profit estimates on Dupixent strength - Reuters
- 3 days ago - Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewsWire
- 3 days ago - Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga